CN102423318B - 亚氯酸盐治疗神经变性疾病 - Google Patents

亚氯酸盐治疗神经变性疾病 Download PDF

Info

Publication number
CN102423318B
CN102423318B CN201110317862.3A CN201110317862A CN102423318B CN 102423318 B CN102423318 B CN 102423318B CN 201110317862 A CN201110317862 A CN 201110317862A CN 102423318 B CN102423318 B CN 102423318B
Authority
CN
China
Prior art keywords
als
disease
chlorite
patients
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201110317862.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102423318A (zh
Inventor
M·S·麦格拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34860199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102423318(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN102423318A publication Critical patent/CN102423318A/zh
Application granted granted Critical
Publication of CN102423318B publication Critical patent/CN102423318B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201110317862.3A 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病 Expired - Lifetime CN102423318B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03
CN2005800037236A CN101102781B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800037236A Division CN101102781B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Publications (2)

Publication Number Publication Date
CN102423318A CN102423318A (zh) 2012-04-25
CN102423318B true CN102423318B (zh) 2015-09-09

Family

ID=34860199

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201110317862.3A Expired - Lifetime CN102423318B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病
CN2005800037236A Expired - Lifetime CN101102781B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2005800037236A Expired - Lifetime CN101102781B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Country Status (7)

Country Link
US (5) US7105183B2 (enExample)
EP (2) EP1711191B1 (enExample)
JP (3) JP5072367B2 (enExample)
CN (2) CN102423318B (enExample)
AU (1) AU2005213300B2 (enExample)
CA (2) CA2838392C (enExample)
WO (1) WO2005076819A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006009506A1 (en) * 2004-07-16 2006-01-26 Gyros Patent Ab Sequential method
MX2007013985A (es) 2005-05-09 2008-02-22 Theranos Inc Sistemas de fluidos de punto de cuidado y usos de los mismos.
DK1915620T3 (da) * 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) * 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
AU2010308329B2 (en) 2009-10-19 2016-10-13 Labrador Diagnostics Llc Integrated health data capture and analysis system
EP2545381A1 (en) * 2010-03-10 2013-01-16 Yeda Research And Development Co. Ltd. Cellular blood markers for early diagnosis of als and for als progression
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
KR101847669B1 (ko) * 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN107759690A (zh) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2945179A1 (en) * 2014-05-16 2015-11-19 Michael S. Mcgrath Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
JP2025518546A (ja) * 2022-05-19 2025-06-17 ニューヴィヴォ， インコーポレイテッド 神経変性疾患のバイオマーカー
US20250114396A1 (en) * 2023-07-07 2025-04-10 The Regents Of The University Of California Chlorite uses for stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507285A (en) * 1982-04-10 1985-03-26 Kuehne Friedrich Wilhelm Stabilized activated oxygen and pharmaceutical compositions containing said stabilized activated oxygen
CN1433481A (zh) * 1999-11-30 2003-07-30 奥克索化学有限公司 通过基因表达分析评价和预测临术预后

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
AU754928B2 (en) 1997-10-06 2002-11-28 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507285A (en) * 1982-04-10 1985-03-26 Kuehne Friedrich Wilhelm Stabilized activated oxygen and pharmaceutical compositions containing said stabilized activated oxygen
CN1433481A (zh) * 1999-11-30 2003-07-30 奥克索化学有限公司 通过基因表达分析评价和预测临术预后

Also Published As

Publication number Publication date
US20060159775A1 (en) 2006-07-20
US20170065634A1 (en) 2017-03-09
CA2554511C (en) 2016-01-19
US8029826B2 (en) 2011-10-04
EP1711191A2 (en) 2006-10-18
JP2012067110A (ja) 2012-04-05
EP2574342B1 (en) 2018-03-07
WO2005076819A2 (en) 2005-08-25
CA2838392A1 (en) 2005-08-25
US20110053186A1 (en) 2011-03-03
CA2554511A1 (en) 2005-08-25
JP5072367B2 (ja) 2012-11-14
AU2005213300A1 (en) 2005-08-25
JP2007520554A (ja) 2007-07-26
WO2005076819A3 (en) 2006-04-13
US20120295296A1 (en) 2012-11-22
US9364501B2 (en) 2016-06-14
EP1711191A4 (en) 2008-12-17
CN101102781B (zh) 2012-06-20
CA2838392C (en) 2017-04-04
JP2015205901A (ja) 2015-11-19
EP2574342A1 (en) 2013-04-03
AU2005213300B2 (en) 2011-06-16
CN102423318A (zh) 2012-04-25
US20050181068A1 (en) 2005-08-18
EP1711191B1 (en) 2014-03-19
CN101102781A (zh) 2008-01-09
US7105183B2 (en) 2006-09-12
JP5797083B2 (ja) 2015-10-21

Similar Documents

Publication Publication Date Title
CN101102781B (zh) 亚氯酸盐治疗神经变性疾病
MacLeod et al. Frequency and morbidity of severe hypoglycaemia in insulin‐treated diabetic patients
Beekman et al. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
Branigan et al. Efficacy of treatment and recurrence rate of leukocytospermia in infertile men with prostatitis
US20100173881A1 (en) Compositions for the treatment of inflammatory disorders
CN102573500A (zh) 巨噬细胞相关疾病的治疗
Bologna et al. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis
Téllez-Zenteno et al. Prognostic factors of thymectomy in patients with myasthenia gravis: a cohort of 132 patients
Dominguez et al. Long term outcomes in patients with anti-DPPX autoimmunity
AU2014203207B2 (en) Chlorite in the treatment of neurodegenerative disease
Barohn et al. Soluble terminal complement components in human myasthenia gravis
Almurakshi et al. Secondary syphilis presents as palmoplantar Hyperpigmented Maculopapules: a case report
Eurelings et al. Sural nerve T cells in demyelinating polyneuropathy associated with monoclonal gammopathy
Haupt et al. Severity of symptoms and rate of progression in Alzheimer's disease: A comparison of cases with early and late onset
Frenkel et al. Perinatal HIV infection and AIDS
Viola What is Alzheimer’s disease?
REYNOLDS et al. Syphilis: a review of the recent literature
Heyes et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific
Underwood Robert R. Kierland, Paul A. O'Leary,* and
de Almeida et al. Dysregulated CSF metalloproteinases in people with HIV despite CSF and peripheral blood suppression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20150909